Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737952 | 0.87 | HRH3 (0.33) | HRH3SLC6A4 | |
| SCHEMBL738008 | 0.86 | HRH3 (0.41) | HRH3 | |
| SCHEMBL1195455 | 0.81 | — | — | |
| SCHEMBL17457985 | 0.80 | — | — | |
| Bromide SCHEMBL31466403 | 0.77 | CYP3A4 (0.31) | CYP3A4CYP2D6HRH1 | |
| SCHEMBL1952683 | 0.77 | CYP3A4 (0.31) | CYP3A4CYP2D6HRH1 | |
| SCHEMBL2442184 | 0.77 | CYP3A4 (0.31) | CYP3A4CYP2D6HRH1 | |
| SCHEMBL2442188 | 0.77 | ALOX15 (0.46) | CYP3A4CYP2D6HRH1 | |
| SCHEMBL1952685 | 0.77 | KDM4E (0.35) | CYP3A4CYP2D6HRH1 | |
| SCHEMBL6890281 | 0.77 | S1PR4 (0.35) | HRH3SLC6A4CYP3A4CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3862354-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2021-08-11 | — | — | EP | claimed |
| EP-2824105-B1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2021-03-31 | — | — | EP | claimed |
| EP-2824105-A1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2015-01-14 | — | — | EP | claimed |
| US-8530493-B2 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2013-09-10 | — | — | US | claimed |
| US-20110027226-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) | 4SC AG (DE) | 2011-02-03 | — | — | US | claimed |
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | claimed |
| EP-2033962-A1 | Tetracyclic indolopyridines as EG5 inhibitors | 4SC AG (DE) | 2009-03-11 | — | — | EP | claimed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | claimed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | claimed |
| EP-3862354-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2021-08-11 | — | — | EP | disclosed |
| EP-2268640-B1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | 4SC AG (DE) | 2016-10-12 | — | — | EP | disclosed |
| EP-2824105-A1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2015-01-14 | — | — | EP | disclosed |
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8557991-B2 | Process for preparing enantiomerically pure indolopyridines | 4SC AG (DE) | 2013-10-15 | — | — | US | disclosed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | MC1R, MCHR2, MCHR1 | HRH3 141/4885SLC6A4 537/4885CYP3A4 908/4885 |
| US-20110027226-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) | KIF5A, KIF5C, KIF5B | HRH3 2340/4885SLC6A4 3222/4885CYP3A4 4309/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HRH3 3/4885SLC6A4 577/4885CYP3A4 525/4885 |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | HRH3 1/4885SLC6A4 1605/4885CYP3A4 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.